Nothing said here yet.
to join the conversation.
Moby summary of OmniAb, Inc.'s Q3 2026 earnings call
Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
OmniAb (NASDAQ:OABI) reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early commercial progress for its xPloration B-cell screening platform.
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and +10.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., October 30, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September…
EMERYVILLE, Calif., October 26, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management’s participation in the following upcoming investor…
OmniAb (NASDAQ:OABI) Chief Financial Officer Kurt Gustafson outlined the company’s antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and…
EMERYVILLE, Calif., October 14, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and…
OmniAb (NASDAQ:OABI) used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides…
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EMERYVILLE, Calif., October 06, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA.
EMERYVILLE, Calif., September 14, 2026--OmniAb, Inc.